Compare Stocks: ENLV, RNTX, PLRX, and PMVP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.11 +0.9%	$3.34	$1.02 ▼ $27.15	$19.23M	1.42	285,113 shs	189,746 shs
PLRX Pliant Therapeutics	$1.14 -2.2%	$1.11	$1.02 ▼ $1.95	$71.83M	1.27	443,194 shs	682,890 shs
PMVP PMV Pharmaceuticals	$1.34 +3.9%	$1.25	$1.02 ▼ $1.88	$68.96M	1.37	621,334 shs	1.16 million shs
RNTX Rein Therapeutics	$0.86 -3.0%	$0.84	$0.69 ▼ $2.18	$76.70M	1.37	467,827 shs	760,328 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+0.91%	-13.28%	-46.63%	-89.00%	-92.88%
PLRX Pliant Therapeutics	-2.16%	+2.25%	+8.10%	-2.16%	-34.39%
PMVP PMV Pharmaceuticals	+3.88%	+3.88%	+12.61%	+26.42%	-4.29%
RNTX Rein Therapeutics	-2.99%	+14.59%	+5.50%	-6.29%	-35.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.11 +0.9%	$3.34	$1.02 ▼ $27.15	$19.23M	1.42	285,113 shs	189,746 shs
PLRX Pliant Therapeutics	$1.14 -2.2%	$1.11	$1.02 ▼ $1.95	$71.83M	1.27	443,194 shs	682,890 shs
PMVP PMV Pharmaceuticals	$1.34 +3.9%	$1.25	$1.02 ▼ $1.88	$68.96M	1.37	621,334 shs	1.16 million shs
RNTX Rein Therapeutics	$0.86 -3.0%	$0.84	$0.69 ▼ $2.18	$76.70M	1.37	467,827 shs	760,328 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+0.91%	-13.28%	-46.63%	-89.00%	-92.88%
PLRX Pliant Therapeutics	-2.16%	+2.25%	+8.10%	-2.16%	-34.39%
PMVP PMV Pharmaceuticals	+3.88%	+3.88%	+12.61%	+26.42%	-4.29%
RNTX Rein Therapeutics	-2.99%	+14.59%	+5.50%	-6.29%	-35.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	22,197.30% Upside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	164.32% Upside
PMVP PMV Pharmaceuticals	2.80	Moderate Buy	$4.33	223.38% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	595.65% Upside

Current Analyst Ratings Breakdown

Latest ENLV, RNTX, PLRX, and PMVP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/20/2026	RNTX Rein Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	$2.95 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	15.55	($1.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	9/11/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A

Latest ENLV, RNTX, PLRX, and PMVP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/11/2026	Q1 2026	ENLV Enlivex Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	193.24	193.24
PLRX Pliant Therapeutics	N/A	9.90	9.90
PMVP PMV Pharmaceuticals	N/A	7.70	7.70
RNTX Rein Therapeutics	N/A	4.27	4.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
PLRX Pliant Therapeutics	97.30%
PMVP PMV Pharmaceuticals	90.20%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
PLRX Pliant Therapeutics	8.74%
PMVP PMV Pharmaceuticals	10.15%
RNTX Rein Therapeutics	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	17.49 million	15.34 million	Optionable
PLRX Pliant Therapeutics	90	61.92 million	56.51 million	Optionable
PMVP PMV Pharmaceuticals	50	53.46 million	48.03 million	Optionable
RNTX Rein Therapeutics	9	86.27 million	84.97 million	N/A

ENLV, RNTX, PLRX, and PMVP Headlines

Recent News About These Companies

Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Consensus Rating of "Hold" from Analysts

September 8 at 6:13 AM | marketbeat.com

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

September 4, 2026 | globenewswire.com

Rein Therapeutics to Present at Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Here's Why You Should Add RNTX Stock to Your Portfolio Now

September 3, 2026 | zacks.com

Velan Capital Investment Management LP Buys New Shares in Rein Therapeutics Inc. $RNTX

September 2, 2026 | marketbeat.com

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

August 20, 2026 | globenewswire.com

Equities Analysts Set Expectations for RNTX FY2026 Earnings

August 20, 2026 | marketbeat.com

What is HC Wainwright's Estimate for RNTX FY2030 Earnings?

August 19, 2026 | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright

August 18, 2026 | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results

August 14, 2026 | marketbeat.com

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 | globenewswire.com

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2026 | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9% - Here's Why

August 10, 2026 | marketbeat.com

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

August 4, 2026 | finance.yahoo.com

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

July 21, 2026 | globenewswire.com

Rein Therapeutics (RNTX) Stock Forecast & Price Target

July 17, 2026 | investing.com

Rein Therapeutics, Inc

June 29, 2026 | edition.cnn.com

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

June 17, 2026 | zacks.com

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

June 11, 2026 | globenewswire.com

Rein Therapeutics Inc RNTX

June 7, 2026 | morningstar.comM

Rein Therapeutics (NASDAQ:RNTX) Director Buys $16,747.50 in Stock

May 29, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, RNTX, PLRX, and PMVP Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.11 +0.01 (+0.91%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+1.35%)

As of 08:38 AM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Pliant Therapeutics NASDAQ:PLRX

$1.14 -0.03 (-2.16%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$1.14 0.00 (0.00%)

As of 08:41 AM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PMV Pharmaceuticals NASDAQ:PMVP

$1.34 +0.05 (+3.88%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$1.35 +0.01 (+0.75%)

As of 09:05 AM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Rein Therapeutics NASDAQ:RNTX

$0.86 -0.03 (-2.99%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.90 +0.03 (+4.00%)

As of 07:58 AM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, RNTX, PLRX, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, RNTX, PLRX, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, RNTX, PLRX, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, RNTX, PLRX, and PMVP Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Pliant Therapeutics NASDAQ:PLRX

PMV Pharmaceuticals NASDAQ:PMVP

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, RNTX, PLRX, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, RNTX, PLRX, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, RNTX, PLRX, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, RNTX, PLRX, and PMVP Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Pliant Therapeutics NASDAQ:PLRX

PMV Pharmaceuticals NASDAQ:PMVP

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools